Get to know our clinical trials
Clinical trial to evaluate the safety and tolerability of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TOD)
THE PURPOSE OF THE STUDY, CALLED VRDN-001-303, IS TO SEE IF VRDN-001 (ALSO REFERRED TO HEREAFTER AS STUDY DRUG) IS SAFE AND TOLERABLE IN THE TREATMENT OF HIS TOE WHEN ADMINISTERED AS A SERIES OF 5 INTRAVENOUS (IV) INFUSIONS
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF VRDN-001, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST THE IGF-1 RECEPTOR, IN PARTICIPANTS WITH THYROID EYE DISEASE (TOD)
- Code EudraCT: 2023-507563-19-00
- Protocol number: VRDN-001-303
- Promoter: Viridian Therapeutics, Inc
- Molecule/Drug: VRDN-001
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.